Medpace Holdings, Inc. Stock price

Equities

MEDP

US58506Q1094

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
403.3 USD +0.13% Intraday chart for Medpace Holdings, Inc. +1.06% +31.56%
Sales 2024 * 2.19B Sales 2025 * 2.54B Capitalization 12.4B
Net income 2024 * 336M Net income 2025 * 409M EV / Sales 2024 * 5.42 x
Net cash position 2024 * 553M Net cash position 2025 * 1.01B EV / Sales 2025 * 4.48 x
P/E ratio 2024 *
38.3 x
P/E ratio 2025 *
31.7 x
Employees 5,900
Yield 2024 *
-
Yield 2025 *
-
Free-Float 81.55%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.13%
1 week+1.06%
Current month+1.45%
1 month-0.08%
3 months+29.26%
6 months+62.61%
Current year+31.56%
More quotes
1 week
398.52
Extreme 398.52
412.62
1 month
384.55
Extreme 384.55
419.42
Current year
277.72
Extreme 277.72
419.42
1 year
181.50
Extreme 181.5
419.42
3 years
126.95
Extreme 126.945
419.42
5 years
52.84
Extreme 52.84
419.42
10 years
21.76
Extreme 21.76
419.42
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 92-06-30
Director of Finance/CFO 49 18-10-31
President 49 07-09-30
Members of the board TitleAgeSince
Director/Board Member 72 18-08-12
Chief Executive Officer 67 92-06-30
Director/Board Member 64 18-08-12
More insiders
Date Price Change Volume
24-03-27 403.3 +0.13% 101,964
24-03-26 402.8 +0.12% 154,504
24-03-25 402.3 -1.59% 124,087
24-03-22 408.8 -1.09% 180,135
24-03-21 413.3 +3.57% 177,096

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
403.3 USD
Average target price
389.5 USD
Spread / Average Target
-3.41%
Consensus
  1. Stock
  2. Equities
  3. Stock Medpace Holdings, Inc. - Nasdaq